August 13, 2020

The Niche

Knoepfler lab stem cell blog

advanced cell technology

5 min read

In the interview below I talk with Dr. Masayo Takahashi, who is leading a team conducting the first ever in-human clinical study based on iPS cells. The work began with patient enrollment on Aug. 1, 2013 in Japan. 1. Can you tell us a bit about your background? As an M.D./Ph.D. and ophthalmologist do you also see patients in addition to doing research? How did you first get interested in stem cells? Are your interests primarily in iPS cells? Yes, I have outpatient clinics in …Read More

3 min read

Every year I do predictions for the stem cell field for the coming year. You can see my full post on my predictions for this year here. Stay tuned soon for my predictions for 2014. How’d I do for 2013 with my predications? Each prediction for this year that I made last year is bolded and my assessment now of how I did for each is in green or red. I did reasonably well for 2013. Sometimes predictions get mixed in with what hopes or …Read More

3 min read

Who do you turn to when you want to both know the real history of the pluripotent stem cell-based biotech industry and perspectives on its future? There are only a handful of people and one of them is definitely Dr. Michael West, CEO of BioTime. I’m doing a several part series of blog posts on a lengthy phone interview and conversation that I had with West. Today in Part 2 we are focused on clinical development of human ES cells and what happened with …Read More

2 min read

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock symbol ACTC) in the early days. He contributed to the team that made human embryonic stem cells (hESC) a reality too. West and I talked at length about the …Read More